author: michael j barry

... Icahn's proxy fight against a proposed acquisition by Mylan Laboratories Inc. (“Mylan”) of King Pharmaceuticals Inc. (“King”) in 2004. Mr. Icahn, through a partnership, controlled a 10% interest in Mylan and had engaged in a vigorous ...